CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation

Summary

This is a multicenter, single arm, phase II study evaluating efficacy in terms of RR in a cohort of NSCLC with MET amplification or MET exon 14 skipping mutation pre-treated or not with MET inhibitors.

Timeline

Start

2018-09-21

Primary completion

2020-09

Completion

2020-09

Drugs

Indications